Epiomic Epidemiology Series: Type 2 diabetes mellitus forecast in 22 major markets 2018–2028

November 2017 | 106 pages | ID: E66B2FC8579EN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Type 2 Diabetes Mellitus in 22 Major Markets

Type 2 diabetes mellitus (T2DM) is a cluster of diseases characterised by high levels of blood glucose, as well as inability of the body to produce sufficient insulin coupled with systemic desensitisation to insulin. Although not exclusively, T2DM is associated with lifestyle factors including unhealthy diet, physical inactivity and obesity. T2DM leads to multiple complications that constitute a serious burden on healthcare systems and causes a 10-year reduction of life expectancy. Diabetes has been recognised by WHO as a global epidemic.

This report provides the current prevalent population for type 2 diabetes mellitus across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Sweden, Denmark, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, some patient parameters and features, as well as several of the main symptoms and co-morbidities of type 2 diabetes mellitus have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for type 2 diabetes mellitus include:

• Chronic kidney disease (CKD)
• Myocardial infarction (MI)
• Stroke
• Lower limb ulcerations & amputations
• Retinopathy
• Glaucoma
• Macular oedema
• Dementia
• Gout
• Chronic heart failure (CHF)
• Neuropathic pain
• Peripheral neuropathy

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global type 2 diabetes mellitus market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of type 2 diabetes mellitus and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on type 2 diabetes mellitus prevalent population.
• Identify sub-populations within type 2 diabetes mellitus which require treatment.
• Gain an understanding of the specific markets that have the largest number of type 2 diabetes mellitus patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR TYPE 2 DIABETES MELLITUS

FEATURES OF TYPE 2 DIABETES MELLITUS PATIENTS

DIAGNOSIS AND TREATMENT STATUS

CLINICAL PARAMETERS

COMORBIDITIES OF TYPE 2 DIABETES MELLITUS PATIENTS

LOWER LIMB ULCERATIONS

OPHTHALMIC CONDITIONS

NEUROPATHY

NEPHROPATHY

MACROVASCULAR DISEASES

OTHER COMORBID CONDITIONS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Criteria for the diagnosis of T2DM
Table 2. Glycaemic control algorithm from the AACE/ACE
Table 3. Prevalence of T2DM, total (000s)
Table 4. Prevalence of T2DM, males (000s)
Table 5. Prevalence of T2DM, females (000s)
Table 6. Patients diagnosed with T2DM, total (000s)
Table 7. Patients diagnosed with T2DM receiving treatment*, total (000s)
Table 8. Patients with T2DM by BMI status, total (000s)
Table 9. Patients with T2DM by total cholesterol, total (000s)
Table 10. T2DM patients with a history of foot ulcerations, total (000s)
Table 11. T2DM patients with a history of infected foot ulcerations, total (000s)
Table 12. T2DM patients with a history of foot ulcerations by wound grading, total (000s)
Table 13. T2DM patients with a history of foot ulcerations by ulcer severity score, total (000s)
Table 14. T2DM patients with a history of foot ulcerations (multiple ulcers), total (000s)
Table 15. T2DM patients with retinopathy, total (000s)
Table 16. T2DM patients with retinopathy by severity of the condition, total (000s)
Table 17. T2DM patients with macular oedema, total (000s)
Table 18. Patients with T2DM by peripheral neuropathy status, total (000s)
Table 19. T2DM patients with neuropathic pain, total (000s)
Table 20. Patients with T2DM by nephropathy status, total (000s)
Table 21. Patients with T2DM by peripheral arterial disease status, total (000s)
Table 22. T2DM patients with chronic heart failure, total (000s)
Table 23. T2DM patients with coronary artery disease, total (000s)
Table 24. T2DM patients with a history of myocardial infarction, total (000s)
Table 25. T2DM patients with a history of stroke, total (000s)
Table 26. T2DM patients with hypertension, total (000s)
Table 27. T2DM patients with atrial fibrillation, total (000s)
Table 28. T2DM patients with dyslipidaemia, total (000s)
Table 29. T2DM patients with nocturia, total (000s)
Table 30. T2DM patients with Alzheimer's disease, total (000s)
Table 31. T2DM patients with gout, total (000s)
Table 32. T2DM patients with tinea pedis, total (000s)
Table 33. T2DM patients with onychomycosis, total (000s)
Table 34. T2DM patients with gastroparesis, total (000s)
Table 35. Abbreviations and Acronyms used in the report
Table 36. USA Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 37. USA Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 38. Canada Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 39. Canada Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 40. France Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 41. France Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 42. Germany Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 43. Germany Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 44. Italy Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 45. Italy Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 46. Spain Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 47. Spain Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 48. UK Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 49. UK Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 50. Poland Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 51. Poland Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 52. Netherlands Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 53. Netherlands Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 54. Norway Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 55. Norway Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 56. Sweden Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 57. Sweden Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 58. Denmark Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 59. Denmark Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 60. Russia Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 61. Russia Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 62. Turkey Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 63. Turkey Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 64. Japan Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 65. Japan Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 66. China Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 67. China Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 68. South Korea Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 69. South Korea Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 70. India Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 71. India Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 72. Australia Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 73. Australia Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 74. Brazil Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 75. Brazil Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 76. Mexico Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 77. Mexico Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)
Table 78. Argentina Prevalence of type 2 diabetes mellitus by 5-yr age cohort, males (000s)
Table 79. Argentina Prevalence of type 2 diabetes mellitus by 5-yr age cohort, females (000s)